18 active not recruiting. 18 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Active not recruiting 18 |
| Phase 2 | 5 | Active not recruiting 5 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) RO7812653, Placebo - Alzheimer's Disease | Phase 1 | Active not recruiting | Hoffmann-La Roche | 6 | 2026-01-27 | 2026-09-09 |
| Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD) Door-through-door companion rideshare, Curb-to-curb rideshare services - Alzheimer Disease or Associated Disorder, Dementia | Phase 1 | Active not recruiting | Onward Health, Inc | 120 | 2025-08-29 | 2026-07-21 |
| A Study to Assess THN391 in Subjects With Alzheimer's Disease THN391, Placebo - Alzheimer Disease, Early Onset | Phase 1 | Active not recruiting | Therini Bio, Inc. | 19 | 2025-07-17 | 2026-07-08 |
| Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study Emtricitabine (FTC), Descovy® (TAF/FTC), Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg. - Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD) | Phase 1 | Active not recruiting | National University Hospital, Singapore | 48 | 2025-06-30 | 2026-08-10 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) PMN310, Placebo - Alzheimer Disease, Early Onset | Phase 1 | Active not recruiting | ProMis Neurosciences, Inc | 144 | 2024-12-13 | 2026-07-13 |
| Study in Subjects With Mild-to-Moderate Alzheimer's Dementia ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Alzamend Neuro, Inc. | 30 | 2023-07-05 | 2026-09-30 |
| Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease LX1001 - Alzheimer Disease | Phase 1 | Active not recruiting | Lexeo Therapeutics | 10 | 2023-05-08 | 2025-07-01 |
| A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003. Aricept Tablet, IVL3003 - Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Inventage Lab., Inc. | 62 | 2023-04-01 | 2024-12-19 |
| Study of AV-1959D, an Amyloid Beta Vaccine AV-1959D, Placebo - Alzheimer Disease | Phase 1 | Active not recruiting | Institute for Molecular Medicine | 48 | 2023-02-27 | 2026-03-27 |
| Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants NIO752, Matching placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 38 | 2023-02-23 | 2026-09-18 |
| R21 Roche: 3-Way Tau Tracers in AD [18F]RO-948, 18F-MK6240, 18F-GTP1 - Alzheimer Disease | Phase 1 | Active not recruiting | Washington University School of Medicine | 38 | 2023-02-01 | 2026-05-08 |
| Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants OLX-07010 Active, OLX-07010 Placebo - Alzheimer Disease | Phase 1 | Active not recruiting | Oligomerix, Inc | 76 | 2023-01-20 | 2026-07-28 |
| ALSENLITE: Senolytics for Alzheimer's Disease Dasatinib, Quercetin - Mild Cognitive Impairment, Alzheimer Disease | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-07-06 | 2026-07-17 |
| Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol) - Alzheimer Disease | Phase 1 | Active not recruiting | Tharick Pascoal | 822 | 2022-03-02 | 2026-09-08 |
| A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment AAV2-BDNF Gene Therapy - Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Active not recruiting | Mark Tuszynski | 12 | 2022-02-07 | 2026-07-10 |
| Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease RO7126209, Placebo - Alzheimers Disease | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 241 | 2021-03-15 | 2026-09-14 |
| A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy UCB0107 (bepranemab) - Progressive Supranuclear Palsy | Phase 1 | Active not recruiting | UCB Biopharma SRL | 19 | 2020-11-16 | 2026-08-03 |
Alzheimer Disease (17) · Cognitive Dysfunction (5) · Dementia (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Memory Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Supranuclear Palsy, Progressive (1)
Brain Diseases (17) · Central Nervous System Diseases (17) · Mental Disorders (17) · Nervous System Diseases (17) · Neurodegenerative Diseases (17) · Neurocognitive Disorders (16) · Dementia (15) · Cognition Disorders (5) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Basal Ganglia Diseases (1) · Cranial Nerve Diseases (1) · Eye Diseases (1)
(18F)GTP1 (1) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Dasatinib (1) · Donepezil (1) · Dronabinol (1) · Emtricitabine (1) · Quercetin (1) · Racivir (1) · emtricitabine tenofovir alafenamide (1) · flutemetamol (1) · nabiximols (1) · tenofovir alafenamide (1)
Hoffmann-La Roche (2) · Alzamend Neuro, Inc. (1) · Federal University of Latin American Integration (1) · Institute for Molecular Medicine (1) · Inventage Lab., Inc. (1) · Lexeo Therapeutics (1) · Mark Tuszynski (1) · Mayo Clinic (1) · National University Hospital, Singapore (1) · Novartis Pharmaceuticals (1) · Oligomerix, Inc (1) · Onward Health, Inc (1) · ProMis Neurosciences, Inc (1) · Tharick Pascoal (1) · Therini Bio, Inc. (1)
United States (11) · Spain (5) · United Kingdom (4) · Canada (3) · Australia (2) · Netherlands (2) · Sweden (2) · Belgium (1) · Brazil (1) · Chile (1) · Finland (1) · France (1) · Germany (1) · Japan (1) · Poland (1)
Christopher Chen (1) · Kimberly Wachter Petty, MBA (1) · Madhav Thambisetty, MD PhD (1) · Mark Tuszynski, M.D., Ph.D. (1) · Michael Agadjanyan, PhD (1) · Nuno Mendonca, MD (1) · Tammie L.S. Benzinger (1) · Tharick Pascoal, MD, PhD (1) · Vijay K. Ramanan, MD, PhD (1)
PMID 19198615, PMID 21358740, PMID 24068826, PMID 26302439, PMID 34366147, PMID 39422960, PMID 40009460, PMID 42208563
2023 (1), 2025 (1), R01AG073267 (1), R01AG074983 (1), R44AG085945 (1)